(Total Views: 238)
Posted On: 07/13/2017 5:08:47 PM
Post# of 72446
Mild to moderate UP? I thought that was for Cohort 1 (and maybe 2) but Cohort 3 was for moderate to severe.
Pics were quite impressive. Other data pretty much mirrored what was given earlier but the Cohort 3 info was impressive.
IMO we showed B to be the powerhouse we thought for the entire IBD spectrum of problems, well tolerated by the body, and very strong in improving quality of life for patients.
Don't think this is going to change our share price much, but it certainly makes a partnership a high probability later this year.
Pics were quite impressive. Other data pretty much mirrored what was given earlier but the Cohort 3 info was impressive.
IMO we showed B to be the powerhouse we thought for the entire IBD spectrum of problems, well tolerated by the body, and very strong in improving quality of life for patients.
Don't think this is going to change our share price much, but it certainly makes a partnership a high probability later this year.
(2)
(0)
